비교리스트

 카트 문의
시장보고서
상품코드
1564921

세계의 B형 간염 백신 시장

Hepatitis B Vaccines
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 182 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

B형 간염 백신 세계 시장은 2030년까지 39억 달러에 달할 것으로 전망

2023년 29억 달러로 추정되는 B형 간염 백신 세계 시장은 2023년부터 2030년까지 연평균 4.3% 성장하여 2030년에는 39억 달러에 달할 것으로 예상됩니다. 이 보고서에서 분석한 부문 중 하나인 성인용 애플리케이션은 CAGR 4.2%를 기록하여 분석 기간 종료 시점에 27억 달러에 도달할 것으로 예상됩니다. 소아 애플리케이션의 성장률은 분석 기간 동안 CAGR 4.6%로 추정됩니다.

미국 시장은 7억 8,130만 달러로 추정, 중국은 CAGR 6.8%로 성장할 것으로 전망

미국 B형 간염 백신 시장은 2023년 7억 8,130만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2023-2030년 분석 기간 동안 6.8%의 CAGR을 기록하며 2030년까지 8억 1,460만 달러의 시장 규모에 도달할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 분석 기간 동안 각각 2.6%와 3.6%의 CAGR을 기록할 것으로 예상됩니다. 유럽에서는 독일이 연평균 3.1%의 성장률을 보일 것으로 예상됩니다.

세계 B형 간염 백신 시장 - 주요 동향 및 촉진요인 요약

B형 간염 백신은 세계 간 건강의 핵심인가?

B형 간염 백신은 가장 널리 퍼져 있고 사망에 이를 수 있는 바이러스 감염을 예방할 수 있는 중요한 도구이지만, B형 간염(HBV)은 간을 공격하는 바이러스 감염으로 간경변증과 간암과 같은 급성 및 만성 간 질환을 유발합니다. 간경변증, 간암 등의 간질환을 유발합니다. 혈액과 같은 감염성 체액에 접촉하여 감염되기 때문에 전 세계적으로 심각한 건강 문제가 되고 있습니다. 만성 HBV 감염은 수십 년 동안 지속될 수 있으며, 증상이 없는 경우가 많지만 시간이 지남에 따라 심각한 간 손상과 합병증을 유발할 수 있습니다. 세계보건기구(WHO)의 추산에 따르면, 2억 9,600만 명 이상의 사람들이 만성 B형 간염을 앓고 있으며, 매년 약 82만 명이 B형 간염으로 인한 합병증으로 사망하고 있습니다.

B형 간염 백신은 B형 간염 바이러스 감염과 그 결과를 예방하는 데 매우 효과적이며, B형 간염 백신은 면역 체계를 자극하여 B형 간염 바이러스에 대한 항체를 생성하여 B형 간염 바이러스에 감염되어도 감염되지 않도록 합니다. 이 백신은 여러 차례에 걸쳐 접종되며, 현존하는 백신 중 가장 효과적인 백신 중 하나로 간주되어 대부분의 사람들에게 장기적인 면역을 제공합니다. 실제로 B형 간염 예방접종은 출생 시 모든 영유아와 의료 종사자 및 만성 간 질환 환자를 포함한 고위험군 성인에게 권장되고 있습니다. 백신 접종이 널리 보급되면 각국은 새로운 HBV 감염 발생을 크게 줄일 수 있으며, 궁극적으로 간암이나 간경변증과 같은 만성 B형 간염의 장기적인 합병증을 예방할 수 있습니다.

B형 간염 백신 개발은 어떻게 기술이 발전했는가?

기술의 발전으로 B형 간염 백신의 안전성, 유효성 및 접근성이 크게 향상되어 보다 효과적이고 널리 보급될 수 있게 되었습니다. 1세대 B형 간염 백신은 감염된 사람의 혈장에서 추출한 것으로, 혈액을 통한 감염의 위험과 높은 생산 비용으로 인해 1980년대에 재조합 DNA 기술이 도입되면서 백신 생산에 혁명을 일으켰고, 현재 표준이 된 재조합 B형 간염 백신이 개발되었습니다. 이 백신은 B형 간염 표면 항원(HBsAg) 유전자를 효모 등의 세포에 삽입하여 항원을 생산하게함으로써 제조됩니다. 이 항원을 채취하여 백신을 만들기 때문에 사람의 혈액 제제가 필요하지 않아 매우 효과적이고 안전한 예방접종 방법을 제공합니다.

B형 간염, 디프테리아, 파상풍, 백일해(DTaP)에 대한 예방이 결합된 백신과 같은 예방 백신은 종합적인 예방 효과를 제공하면서도 주사 횟수를 줄일 수 있는 소아기 예방접종 프로그램에 특히 유용합니다. 이는 물류 문제로 인해 백신 접종이 어려운 저자원 환경에서 특히 중요합니다.

또한, 보조제(면역 반응을 높이기 위해 백신에 첨가되는 물질)에 대한 연구로 B형 간염 백신의 효과가 향상되고 있습니다. 최근 B형 간염 백신에는 신체의 면역 반응을 향상시키는 보조제가 포함되어 있어 더 강력하고 오래 지속되는 면역력을 보장합니다. 또한, 일부 백신은 환자의 순응도 및 접근성을 높이기 위해 더 적은 용량으로 처방되는 백신도 있습니다. 마이크로니들 패치와 같은 새로운 전달 시스템의 사용은 특히 전통적인 주사 방법이 어려운 환경에서 백신을 보다 간편하고 덜 침습적으로 투여할 수 있도록 연구되고 있습니다. 이러한 기술 혁신은 B형 간염 백신의 효능을 향상시킬 뿐만 아니라 전 세계 예방접종 활동에서 보다 실용적이고 확장 가능한 백신으로 발전하고 있습니다.

B형 간염 백신은 왜 세계 보건에 중요한가?

B형 간염 백신은 전 세계적으로 간 질환과 암의 주요 원인인 B형 간염 바이러스에 대한 효과적인 방어책을 제공하기 때문에 세계 보건에 매우 중요합니다. B형 간염은 전염성이 강하고 혈액, 성접촉, 출산 시 모체에서 태아에게 전염될 수 있습니다. 백신을 접종하지 않으면 B형 간염에 걸린 어머니에게서 태어난 아기는 만성 감염자가 될 위험이 높으며, 평생 심각한 간 질환을 앓을 위험이 있습니다. 생후 24시간 이내에 신생아에게 백신을 접종하는 것은 모자 감염을 예방하는 가장 효과적인 방법 중 하나이며, 공중보건 위협인 B형 간염을 퇴치하기 위한 전 세계 노력의 핵심입니다.

B형 간염이 유행하는 지역, 특히 아프리카와 아시아 일부 지역에서는 이 질병의 부담이 엄청납니다. 많은 사람들이 어린 시절에 감염되며, 바이러스는 수십 년 동안 체내에 남아 간경변증과 간암과 같은 만성 간 질환을 유발하는 경우가 많습니다. B형 간염 백신을 광범위하게 접종하면 만성 B형 간염 감염률과 간암과 같은 관련 질환의 발생률이 크게 감소하는 것으로 나타났는데, 백신 접종이 없다면 이들 지역은 막대한 의료 비용과 B형 간염 관련 합병증으로 인한 인명 손실에 직면하게 됩니다. 보편적인 B형 간염 백신 접종 프로그램을 시행한 국가에서는 바이러스와 그 합병증의 유병률이 크게 감소하여 백신이 공중 보건을 보호하는 데 있어 백신의 역할이 강조되고 있습니다.

B형 간염 백신은 의료 종사자, 만성 간 질환 환자, 감염된 혈액이나 체액에 노출될 가능성이 있는 사람 등 취약 계층을 보호하는 데도 매우 중요합니다. 특히 의료 종사자는 직업상 HBV에 노출될 위험이 있어 예방접종은 감염에 대한 필수적인 예방책이며, C형 간염과 간경변증을 포함한 만성 간질환 환자의 경우, B형 간염 예방접종으로 추가 간 손상을 예방하고 간부전 위험을 줄일 수 있습니다. 전반적으로 B형 간염 백신은 위험한 바이러스 감염으로부터 개인을 보호할 뿐만 아니라, 간암 발생률을 낮추고 전 세계적으로 건강 결과를 개선하기 위한 광범위한 공중보건 노력에 기여합니다.

B형 간염 백신 시장의 성장을 촉진하는 요인은 무엇인가?

B형 간염 백신 시장의 성장은 질병에 대한 인식 개선, 백신 접종 프로그램 확대, 백신 개발의 진전 등 몇 가지 주요 요인에 의해 주도되고 있습니다. 주요 요인 중 하나는 간 질환과 간암의 주요 원인인 B형 간염의 세계적 부담에 대한 인식이 높아지고 있다는 점입니다. 각국 정부와 공중보건 기관은 특히 B형 간염 바이러스가 유행하는 지역에서 예방접종 보급을 통해 B형 간염 바이러스의 발병을 줄이기 위한 노력을 강화하고 있습니다. 세계보건기구(WHO)는 2030년까지 공중보건 위협인 바이러스성 간염을 퇴치하겠다는 목표를 세우고, 이를 위해 예방접종 프로그램에 대한 투자를 늘리고 B형 간염 백신 접종의 중요성에 대한 인식을 높이기 위해 보다 적극적인 공중보건 캠페인을 전개하고 있습니다.

특히 중저소득 국가에서 백신 접종률의 증가도 시장을 이끄는 중요한 요인입니다. 세계 간염 계획 및 백신 동맹 Gavi와 같은 국제 이니셔티브는 서비스가 충분하지 않은 지역에서 B형 간염 백신에 대한 접근성을 확대하는 데 중요한 역할을 하고 있습니다. 이러한 프로그램은 국가들이 신생아에 대한 보편적 예방접종을 시행하고, HBV 감염 위험이 높은 성인도 백신을 접종할 수 있도록 재정적 지원과 지원을 제공하고 있으며, B형 간염 백신을 국가 예방접종 일정에 포함시키는 국가가 늘어남에 따라 B형 간염 백신에 대한 수요도 증가하고 있습니다. B형 간염 백신에 대한 수요는 지속적으로 증가하고 있습니다.

백신 개발의 기술적 진보도 시장 성장에 기여하고 있습니다. 재조합 백신의 개발로 B형 간염 예방접종이 보다 안전하고 효과적이며, 혼합 백신의 출현으로 소아 및 성인 집단에서 예방접종의 편의성이 향상되었으며, 한 번의 접종으로 여러 질병을 예방할 수 있는 혼합 백신은 물류상의 문제로 인해 예방접종을 방해할 수 있는 대규모 예방접종 프로그램에 특히 유용합니다. 예방접종을 방해할 수 있는 대규모 예방접종 프로그램에서 특히 유용합니다. 또한, 마이크로니들 패치나 바늘이 필요 없는 주사기 등 백신 투여의 혁신은 특히 외딴 지역이나 자원이 부족한 환경에서 B형간염 백신의 접근성을 더욱 향상시킬 수 있습니다.

마지막으로, B형 간염과 간암의 연관성에 대한 대중의 인식이 높아지면서 백신 접종에 대한 수요가 증가하고 있습니다. 예방 의료에 대한 관심이 높아지면서 만성 B형 간염의 가장 심각한 합병증 중 하나인 간암 발병 위험을 줄이기 위해 HBV 백신을 접종하면 장기적으로 얻을 수 있는 이점이 개인과 의료 서비스 제공자에게 인식되고 있습니다. 공중보건 기관들이 보다 광범위한 예방접종과 B형 간염 퇴치를 지속적으로 옹호하고 있는 가운데, B형 간염 백신 시장은 꾸준히 성장하고 있으며, 백신이 전 세계 간 건강 및 질병 예방의 중요한 도구로서 그 역할이 강화될 것으로 예상됩니다.

조사 대상 기업 예시(주목받는 14개 기업)

  • Beijing Minhai Biotechnology Co., Ltd.
  • Bharat Biotech International Ltd.
  • Binnopharm Group LLC
  • Biokangtai
  • CSL Ltd.
  • Dynavax Technologies Corporation
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline PLC
  • Hualan Biological Engineering Co., Ltd.
  • Merck & Co., Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 24.10.11

Global Hepatitis B Vaccines Market to Reach US$3.9 Billion by 2030

The global market for Hepatitis B Vaccines estimated at US$2.9 Billion in the year 2023, is expected to reach US$3.9 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2023-2030. Adult Application, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Pediatric Application segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$781.3 Million While China is Forecast to Grow at 6.8% CAGR

The Hepatitis B Vaccines market in the U.S. is estimated at US$781.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$814.6 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Hepatitis B Vaccines Market - Key Trends and Drivers Summarized

Are Hepatitis B Vaccines the Cornerstone of Global Liver Health?

Hepatitis B vaccines are critical tools in preventing one of the most widespread and potentially deadly viral infections, but why are these vaccines so essential? Hepatitis B (HBV) is a viral infection that attacks the liver, leading to both acute and chronic liver disease, including cirrhosis and liver cancer. It is transmitted through contact with infectious body fluids, such as blood, making it a significant global health concern. Chronic HBV infection can persist for decades, often without symptoms, but can lead to severe liver damage and complications over time. The World Health Organization (WHO) estimates that over 296 million people are living with chronic hepatitis B, with nearly 820,000 deaths each year attributed to complications from the disease.

The hepatitis B vaccine is highly effective in preventing HBV infection and its consequences. It works by stimulating the immune system to produce antibodies against the hepatitis B virus, thereby protecting individuals from becoming infected if they are exposed to the virus. The vaccine is administered in a series of shots and is considered one of the most effective vaccines available, providing long-lasting immunity in most individuals. In fact, vaccination against hepatitis B is recommended for all infants at birth, as well as for high-risk adults, including healthcare workers and individuals with chronic liver disease. With widespread vaccination, countries can drastically reduce the incidence of new HBV infections, ultimately preventing the long-term complications of chronic hepatitis B, such as liver cancer and cirrhosis.

How Has Technology Advanced Hepatitis B Vaccine Development?

Technological advancements have significantly improved the safety, efficacy, and accessibility of hepatitis B vaccines, making them more effective and widely available. The first-generation hepatitis B vaccines were derived from the blood plasma of infected individuals, but this method posed risks related to blood-borne infections and was expensive to produce. The introduction of recombinant DNA technology in the 1980s revolutionized vaccine production, leading to the development of recombinant hepatitis B vaccines, which are now the standard. These vaccines are made by inserting the gene for the hepatitis B surface antigen (HBsAg) into yeast or other cells, which then produce the antigen. The antigen is harvested and used to create the vaccine, offering a highly effective and safe method for immunization without the need for human blood products.

Further advancements have led to the creation of combination vaccines that protect against multiple diseases, including hepatitis B. These vaccines, such as those that combine protection against hepatitis B, diphtheria, tetanus, and whooping cough (DTaP), are particularly useful in childhood immunization programs, reducing the number of injections required while still providing comprehensive protection. This is especially important in low-resource settings, where logistical challenges can make vaccine delivery difficult.

In addition, research into adjuvants—substances added to vaccines to enhance the immune response—has improved the effectiveness of hepatitis B vaccines. Modern hepatitis B vaccines often include adjuvants that boost the body’s immune response, ensuring stronger and longer-lasting immunity. Some vaccines are also now formulated to require fewer doses, improving patient compliance and accessibility. The use of novel delivery systems, such as microneedle patches, is also being explored to make vaccine administration easier and less invasive, especially in settings where traditional injection methods may be challenging. These technological innovations have not only enhanced the effectiveness of hepatitis B vaccines but have also made them more practical and scalable for use in global immunization efforts.

Why Are Hepatitis B Vaccines Critical for Global Health?

Hepatitis B vaccines are critical for global health because they provide effective protection against a virus that is a leading cause of liver disease and cancer worldwide. Hepatitis B is highly contagious and can be transmitted through blood, sexual contact, and from mother to child during childbirth. Without vaccination, infants born to mothers with hepatitis B have a high risk of becoming chronically infected, leading to a lifetime risk of serious liver disease. Vaccinating newborns within the first 24 hours of life is one of the most effective ways to prevent mother-to-child transmission, and it is a cornerstone of global efforts to eliminate hepatitis B as a public health threat.

In regions where hepatitis B is endemic, particularly in parts of Africa and Asia, the burden of the disease is immense. Many individuals are infected during childhood, and the virus can remain in the body for decades, often leading to chronic liver conditions such as cirrhosis and liver cancer. Without vaccination, these regions face enormous healthcare costs and loss of life due to HBV-related complications. Hepatitis B vaccines, when administered widely, have been shown to significantly reduce the rates of chronic HBV infection and associated diseases, including liver cancer. Countries that have implemented universal hepatitis B vaccination programs have seen dramatic reductions in the prevalence of the virus and its complications, underscoring the vaccine's role in protecting public health.

Hepatitis B vaccines are also crucial for protecting vulnerable populations, such as healthcare workers, people with chronic liver disease, and individuals who may be exposed to infected blood or bodily fluids. Healthcare professionals, in particular, are at risk of occupational exposure to HBV, and vaccination provides an essential safeguard against infection. For individuals with chronic liver disease, including those with hepatitis C or cirrhosis, the added protection from hepatitis B can prevent further liver damage and reduce the risk of liver failure. Overall, the hepatitis B vaccine not only protects individuals from a dangerous viral infection but also contributes to broader public health efforts aimed at reducing liver cancer rates and improving health outcomes globally.

What Factors Are Driving the Growth of the Hepatitis B Vaccine Market?

The growth of the hepatitis B vaccine market is driven by several key factors, including increased awareness of the disease, expanded vaccination programs, and advancements in vaccine development. One of the primary drivers is the growing recognition of the global burden of hepatitis B, which is a leading cause of liver disease and liver cancer. Governments and public health organizations are intensifying efforts to reduce the incidence of HBV through widespread immunization, particularly in regions where the virus is endemic. The World Health Organization (WHO) has set targets for the elimination of viral hepatitis as a public health threat by 2030, which has led to increased investment in vaccination programs and more aggressive public health campaigns to raise awareness about the importance of hepatitis B vaccination.

Expanded vaccination coverage, especially in low- and middle-income countries, is another significant factor driving the market. International initiatives like the Global Hepatitis Programme and Gavi, the Vaccine Alliance, have played key roles in increasing access to the hepatitis B vaccine in underserved regions. These programs provide funding and logistical support to help countries implement universal newborn vaccination and ensure that adults at high risk of HBV infection can also access the vaccine. As more countries adopt routine hepatitis B vaccination as part of their national immunization schedules, the demand for hepatitis B vaccines continues to rise.

Technological advancements in vaccine development have also contributed to market growth. The development of recombinant vaccines has made hepatitis B immunization safer and more effective, while the emergence of combination vaccines has improved the convenience of delivering immunizations in pediatric and adult populations. These combination vaccines, which protect against multiple diseases with a single shot, are particularly valuable in large-scale immunization programs where logistical challenges can hinder vaccine administration. Additionally, innovations in vaccine delivery, such as microneedle patches or needle-free injectors, could further enhance the accessibility of hepatitis B vaccines, particularly in remote or resource-poor settings.

Lastly, growing public awareness of the link between hepatitis B and liver cancer is driving demand for vaccination. With increasing focus on preventive healthcare, individuals and healthcare providers are recognizing the long-term benefits of vaccinating against HBV to reduce the risk of developing liver cancer, one of the most serious complications of chronic hepatitis B. This heightened awareness is encouraging more people to get vaccinated, including adults who may have been overlooked during childhood immunization campaigns. As public health agencies continue to advocate for broader vaccination coverage and the elimination of hepatitis B, the market for hepatitis B vaccines is expected to grow steadily, reinforcing the vaccine’s role as a critical tool in global liver health and disease prevention.

Select Competitors (Total 14 Featured) -

  • Beijing Minhai Biotechnology Co., Ltd.
  • Bharat Biotech International Ltd.
  • Binnopharm Group LLC
  • Biokangtai
  • CSL Ltd.
  • Dynavax Technologies Corporation
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline PLC
  • Hualan Biological Engineering Co., Ltd.
  • Merck & Co., Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Hepatitis B Vaccines - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growth in National Immunization Programs Expands Addressable Market for Hepatitis B Vaccines
    • Growth in Newborn and Pediatric Vaccination Programs Expands Market Opportunities
    • Role of Hepatitis B Vaccines in Preventing Liver Cancer and Chronic Hepatitis Sets Stage for Market Growth
    • Combination Vaccines and Single-dose Solutions Expands Market Potential
    • Increasing Focus on Booster Vaccination Programs for High-risk Populations Drives Demand
    • Growth in Travel and Occupational Health Vaccination Expands Addressable Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hepatitis B Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hepatitis B Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hepatitis B Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Adult by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Pediatric by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Combination Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Combination Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Combination Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Mono Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Mono Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Mono Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Hepatitis B Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Hepatitis B Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: France 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: France 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Germany 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Italy 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: UK 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Spain Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Spain 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Spain 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 119: Russia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Russia Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Russia 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Russia 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Europe 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Europe 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Hepatitis B Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Asia-Pacific 16-Year Perspective for Hepatitis B Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Asia-Pacific 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 149: Australia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Australia Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Australia 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Australia 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • INDIA
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 158: India Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: India Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: India 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 161: India Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: India 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: India 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 167: South Korea Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: South Korea Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: South Korea 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: South Korea 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Rest of Asia-Pacific Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Rest of Asia-Pacific 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 185: Latin America Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 186: Latin America Historic Review for Hepatitis B Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Latin America 16-Year Perspective for Hepatitis B Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Latin America 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 197: Argentina Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Argentina Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Argentina 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Argentina 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 206: Brazil Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Brazil Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Brazil 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Brazil 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 215: Mexico Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Mexico Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Mexico 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Mexico 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Rest of Latin America Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Rest of Latin America 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Rest of Latin America 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 233: Middle East Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 234: Middle East Historic Review for Hepatitis B Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Middle East 16-Year Perspective for Hepatitis B Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Middle East 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 245: Iran Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Iran Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Iran 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Iran 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 254: Israel Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Israel Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Israel 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Israel 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Saudi Arabia Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Saudi Arabia 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Saudi Arabia 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 272: UAE Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: UAE Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: UAE 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: UAE 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Rest of Middle East Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Rest of Middle East 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: Rest of Middle East 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • AFRICA
    • Hepatitis B Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 290: Africa Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Application - Adult and Pediatric - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Africa Historic Review for Hepatitis B Vaccines by Application - Adult and Pediatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: Africa 16-Year Perspective for Hepatitis B Vaccines by Application - Percentage Breakdown of Value Sales for Adult and Pediatric for the Years 2014, 2024 & 2030
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Hepatitis B Vaccines by Type - Combination Vaccines and Mono Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Africa 16-Year Perspective for Hepatitis B Vaccines by Type - Percentage Breakdown of Value Sales for Combination Vaccines and Mono Vaccines for the Years 2014, 2024 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Hepatitis B Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제